Back to Journals » OncoTargets and Therapy » Volume 9

Sensitivity value of hematological markers in patients receiving chemoradiotherapy for esophageal squamous cell carcinoma

Authors Zhu S, Miao CW, Wang ZT, Peng L, Li B

Received 15 June 2016

Accepted for publication 11 September 2016

Published 13 October 2016 Volume 2016:9 Pages 6187—6193

DOI https://doi.org/10.2147/OTT.S115011

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 2

Editor who approved publication: Dr William Cho


Shan Zhu,1,2,* Chuan-Wang Miao,1,2,* Zhong-Tang Wang,2 Li Peng,3 Baosheng Li2

1School of Medicine and Life Sciences, Shandong Academy of Medical Sciences, University of Jinan, 2Department of Radiotherapy, 3Department of Clinical Laboratory, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, People’s Republic of China

*These authors contributed equally to this work

Background: Hematological markers of the systemic inflammatory response (SIR) including the neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and the combination of NLR with PLR (CNP) are associated with prognosis of patients with esophageal squamous cell carcinoma (ESCC). However, their value in predicting the sensitivity to chemoradiotherapy in patients with ESCC is unclear. The aim of this study was to investigate whether these markers can be used as sensitivity predictors for chemoradiotherapy in patients with ESCC.
Patients and methods: A total of 114 patients with newly diagnosed ESCC were retrospectively evaluated. They were treated with curative intent by primary radiotherapy only or concurrent chemoradiotherapy. These patients were grouped for further analysis according to the optimum cutoff values of NLR, PLR, and CNP. A univariate analysis was conducted to compare the ability of each of the hematological markers of SIR and clinicopathological characteristics. Multivariate analysis was performed to identify whether the markers were associated with the sensitivity to chemoradiotherapy. The relationship between clinicopathological characteristics and hematological markers was assessed.
Results: NLR, CNP, T stage, M stage, and clinical stage were significantly associated with the sensitivity to chemoradiotherapy. In multivariate analysis, CNP and clinical stage were the independent risk factors predicting a poorer sensitivity.
Conclusion: This study validated novel, easy-to-use hematological markers and found that CNP, an SIR score, is an independent hematological marker of poor sensitivity to chemoradiotherapy in patients with ESCC. This may help guide the planning of follow-up regimens.
Keywords: hematological markers, systemic inflammatory response, sensitivity to chemoradiotherapy, neutrophil to lymphocyte ratio, platelet to lymphocyte ratio

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]